Venkatesan, Thangam and Hasler, William L and Camilleri, Michael (2026) Cannabinoid hyperemesis syndrome. JAMA, Early online, https://doi.org/10.1001/jama.2026.7873.
External website: https://jamanetwork.com/journals/jama/fullarticle/...
Marijuana, the most common cannabis product, is a mixture of dried flowers, leaves, and seeds from cannabis plants. The primary psychoactive ingredient in cannabis is Δ9 tetrahydrocannabinol (THC). Cannabis is currently legal for treatment and/or recreational purposes in all US states except Idaho and the District of Columbia.1 In 2021, the National Survey on Drug Use and Health documented that 13% of US individuals 12 years and older reported cannabis use within the past month. Use was highest among individuals aged 18 to 25 years (24%), and prevalence of past-month cannabis vaping was 40% among adolescents (aged 12-17 years), 27% among young adults aged 18 to 25 years, and 17.4% among individuals 26 years or older. Based on a 2018 survey of 27 169 individuals aged 16 to 65 years, 27% of adults in the US and Canada had used cannabis for treatment.
A Substance use and dependence > Prevalence > Substance use behaviour > Abstinence
A Substance use and dependence > Effects or consequences
B Substances > Cannabis product / compounds (Plant-derived cannabinoids) > Tetrahydrocannabinol (THC)
B Substances > New (novel) psychoactive substances > NPS cannabinoids > Synthetic cannabinoids (Spice)
B Substances > New (novel) psychoactive substances > NPS cannabinoids > Semi-synthetic cannabinoids (HHC)
E Concepts in biomedical areas > Route of administration > Smoke, vape, inhalation
HA Screening, identification, and diagnostic method > Physical / medical screening, assessment and diagnostic method
J Health care, prevention, harm reduction and treatment > Risk and protective factors > Risk factors
P Demography, epidemiology, and history > Epidemiology
VA Geographic area > International
Repository Staff Only: item control page